(Reuters) -Atai Life Sciences and its partner Recognify Life Sciences said on Friday their experimental drug did not meet the main goal in a mid-stage trial for patients with cognitive impairment linked to schizophrenia.
U.S.-listed shares of atai fell about 14% in extended trading.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Devika Syamnath)
